Table 5.

Adverse events

Adverse events	Total (N = 355)	Group I	Group II
		Cephalexin CV (n = 174)	Cefuroxime (n = 87)	Co-amoxiclav (n = 94)
Alteration of taste
Number of patients (%)	2 (0.6)	0 (0.0)	1 (1.2)	1 (1.5)
Duration
Mean ± SD	4.5 ± 0.7		4.0 ± 0.0	5.0 ± 0.0
Median	5		4	5
Range	4–5		4–4	5–5
Ongoing; n (%)	2 (100.0)	0 (0.0)	1 (100.0)	1 (100.0)
Severity; n (%)
Mild	1 (50.0)	0 (0.0)	1 (100.0)	0 (0.0)
Moderate	1 (50.0)	0 (0.0)	0 (0.0)	1 (100.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Diarrhea
Number of patients (%)	14 (3.9)	3 (1.7)	1 (1.2)	10 (10.6)
Duration
Mean ± SD	5.5 ± 1.9	5.0 ± 1.7	7.0 ± 0.0	5.6 ± 2.1
Median	5	4	7	5
Range	3–9	4–7	7–7	3–9
Ongoing; n (%)	4 (28.6)	0 (0.0)	0 (0.0)	4 (40.0)
Severity; n (%)
Mild	6 (42.8)	2 (66.7)	1 (100.0)	3 (30.0)
Moderate	6 (42.8)	0 (0.0)	0 (0.0)	6 (60.0)
Severe	2 (14.3)	1 (33.3)	0 (0.0)	1 (10.0)
Hyperacidity
Number of patients (%)	2 (0.5)	2 (1.2)	0 (0.0)	0 (0.0)
Duration
Mean ± SD	3.0 ± 1.4	3.0 ± 1.4
Median	3	3
Range	2–4	2–4
Ongoing; n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severity; n (%)
Mild	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Moderate	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)
Severe	1 (50.0)	1 (50.0)	0 (0.0)	0 (0.0)
Nausea
Number of patients (%)	2 (0.5)	2 (1.2)	0 (0.0)	0 (0.0)
Duration
Mean ± SD	2.5 ± 0.7	2.5 ± 0.7
Median	3	3
Range	2–3	2–3
Ongoing; n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severity; n (%)
Mild	2 (100.0)	2 (100.0)	0 (0.0)	0 (0.0)
Moderate	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Skin rashes
Number of patients (%)	1 (0.3)	1 (0.6)	0 (0.0)	0 (0.0)
Duration
Mean ± SD	3.0 ± 0.0	3.0 ± 0.0
Median	3	3
Range	3–3	3–3
Ongoing; n (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severity; n (%)
Mild	1 (100.0)	1 (100.0)	0 (0.0)	0 (0.0)
Moderate	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Severe	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

Co-amoxiclav amoxicillin–clavulanic acid, CV clavulanic acid, n number of patients, N total patients, SD standard deviation